Chromosome Microarray Analysis for the Investigation of Deletions in Pediatric Movement Disorders: A Systematic Review of the Literature.
children
chromosome microarray analysis
deletion
movement disorder
review
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
18
10
2022
revised:
19
01
2023
accepted:
19
02
2023
pmc-release:
16
03
2024
medline:
19
4
2023
entrez:
18
4
2023
pubmed:
19
4
2023
Statut:
epublish
Résumé
Chromosome microarray analysis (CMA) can detect copy number variants (CNV) beyond the resolution of standard G-banded karyotyping. De novo or inherited microdeletions may cause autosomal dominant movement disorders. The purpose of this study was to analyze the clinical characteristics, associated features, and genetic information of children with deletions in known genes that cause movement disorders and to make recommendations regarding the diagnostic application of CMA. Clinical cases published in English were identified in scientific databases (PubMed, ClinVar, and DECIPHER) from January 1998 to July 2019 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Cases with deletions or microdeletions greater than 300 kb were selected. Information collected included age, sex, movement disorders, associated features, and the size and location of the deletion. Duplications or microduplications were not included. A total of 18.097 records were reviewed, and 171 individuals were identified. Ataxia (30.4%), stereotypies (23.9%), and dystonia (21%) were the most common movement disorders. A total of 16% of the patients demonstrated more than one movement disorder. The most common associated features were intellectual disability or developmental delay (78.9%) and facial dysmorphism (57.8%). The majority (77.7%) of microdeletions were smaller than 5 Mb. We find no correlation between movement disorders, their associated features, and the size of microdeletions. Our results support the use of CMA as an investigational test in children with movement disorders. As the majority of identified articles were case reports and small case series (low quality), future efforts should focus on larger prospective studies to examine the causation of microdeletions in pediatric movement disorders.
Sections du résumé
Background
UNASSIGNED
Chromosome microarray analysis (CMA) can detect copy number variants (CNV) beyond the resolution of standard G-banded karyotyping. De novo or inherited microdeletions may cause autosomal dominant movement disorders.
Objectives
UNASSIGNED
The purpose of this study was to analyze the clinical characteristics, associated features, and genetic information of children with deletions in known genes that cause movement disorders and to make recommendations regarding the diagnostic application of CMA.
Methods
UNASSIGNED
Clinical cases published in English were identified in scientific databases (PubMed, ClinVar, and DECIPHER) from January 1998 to July 2019 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Cases with deletions or microdeletions greater than 300 kb were selected. Information collected included age, sex, movement disorders, associated features, and the size and location of the deletion. Duplications or microduplications were not included.
Results
UNASSIGNED
A total of 18.097 records were reviewed, and 171 individuals were identified. Ataxia (30.4%), stereotypies (23.9%), and dystonia (21%) were the most common movement disorders. A total of 16% of the patients demonstrated more than one movement disorder. The most common associated features were intellectual disability or developmental delay (78.9%) and facial dysmorphism (57.8%). The majority (77.7%) of microdeletions were smaller than 5 Mb. We find no correlation between movement disorders, their associated features, and the size of microdeletions.
Conclusions
UNASSIGNED
Our results support the use of CMA as an investigational test in children with movement disorders. As the majority of identified articles were case reports and small case series (low quality), future efforts should focus on larger prospective studies to examine the causation of microdeletions in pediatric movement disorders.
Identifiants
pubmed: 37070051
doi: 10.1002/mdc3.13711
pii: MDC313711
pmc: PMC10105116
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
547-557Informations de copyright
© 2023 International Parkinson and Movement Disorder Society.
Références
Nat Genet. 2017 Feb;49(2):223-237
pubmed: 27992417
Am J Med Genet A. 2012 Jul;158A(7):1633-40
pubmed: 22678713
Mov Disord. 2015 Feb;30(2):262-6
pubmed: 25545641
Am J Med Genet A. 2012 Dec;158A(12):3168-73
pubmed: 23169673
Genet Med. 2015 Aug;17(8):599-609
pubmed: 25569435
Am J Med Genet A. 2016 Nov;170(11):2943-2955
pubmed: 27410714
J Neurol. 2014 Dec;261(12):2296-304
pubmed: 25209853
J Clin Neurosci. 2021 Dec;94:281-285
pubmed: 34863451
Am J Hum Genet. 2009 Apr;84(4):524-33
pubmed: 19344873
Int J Paediatr Dent. 2008 Nov;18(6):441-5
pubmed: 18445003
Genet Med. 2011 Jul;13(7):676-9
pubmed: 21681105
Neurol Neurochir Pol. 2021;55(3):300-305
pubmed: 34037980
Am J Hum Genet. 2016 Dec 1;99(6):1377-1387
pubmed: 27839873
Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1159-85
pubmed: 27495203
Neurobiol Aging. 2019 Feb;74:234.e9-234.e15
pubmed: 30342764
Mov Disord. 2016 Apr;31(4):436-57
pubmed: 27079681
Brain. 2009 Aug;132(Pt 8):2005-25
pubmed: 19578124
PLoS One. 2010 Oct 29;5(10):e13750
pubmed: 21060786
Pediatr Neurol. 2014 Jul;51(1):170-5
pubmed: 24938147
Epilepsia. 2011 Oct;52(10):1820-7
pubmed: 21762454
Eur J Paediatr Neurol. 2018 Mar;22(2):245-256
pubmed: 29289525
J Neurol Sci. 2012 Apr 15;315(1-2):77-81
pubmed: 22166853
Brain Dev. 2016 Mar;38(3):285-92
pubmed: 26482601
Mov Disord. 2013 Jun;28(6):787-94
pubmed: 23677909
Am J Hum Genet. 2010 May 14;86(5):749-64
pubmed: 20466091
J Inherit Metab Dis. 2014 Jul;37(4):627-42
pubmed: 24906253
BMC Med Genet. 2012 Dec 19;13:123
pubmed: 23253088
Mov Disord. 2022 May;37(5):905-935
pubmed: 35481685
J Am Acad Child Adolesc Psychiatry. 2014 Aug;53(8):910-9
pubmed: 25062598
Epilepsia. 2015 May;56(5):707-16
pubmed: 25818041
Mov Disord. 2021 Sep;36(9):2017-2025
pubmed: 34056754
Dev Med Child Neurol. 2012 Jul;54(7):582-3
pubmed: 22515729
J Med Genet. 2014 Jun;51(6):375-87
pubmed: 24714694
Eur J Med Genet. 2007 Jan-Feb;50(1):60-5
pubmed: 17071147
Neurology. 1995 Feb;45(2):325-31
pubmed: 7854534
J Med Genet. 2012 Jun;49(6):366-72
pubmed: 22636604
Epilepsia. 2019 Apr;60(4):689-706
pubmed: 30866059
Mov Disord. 2010 Aug 15;25(11):1538-49
pubmed: 20589866
Dev Med Child Neurol. 2012 Jul;54(7):618-23
pubmed: 22515636
Mov Disord. 2006 Dec;21(12):2237-40
pubmed: 17044090
Neuroreport. 2015 Mar 25;26(5):254-7
pubmed: 25714420
Brain Dev. 2018 Apr;40(4):353-356
pubmed: 29289388
Eur J Med Genet. 2017 May;60(5):257-260
pubmed: 28286255
Hum Mutat. 2008 Feb;29(2):331-2
pubmed: 18205193
Ann Hum Genet. 2015 May;79(3):209-17
pubmed: 25779878
Neurology. 2010 May 18;74(20):1583-90
pubmed: 20427753
Epilepsia. 2015 Dec;56(12):1931-40
pubmed: 26514728
J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):956-62
pubmed: 22832740
Nat Genet. 2013 Jul;45(7):825-30
pubmed: 23708187
Genet Med. 2012 Oct;14(10):868-76
pubmed: 22722545
J Hum Genet. 2015 Apr;60(4):203-6
pubmed: 25608831
J Hum Genet. 2008;53(10):876-885
pubmed: 18651096
Eur J Med Genet. 2018 Jul;61(7):393-398
pubmed: 29477862
Mol Cytogenet. 2010 Nov 09;3:22
pubmed: 21062444
BMC Psychiatry. 2018 Aug 2;18(1):248
pubmed: 30071822
Neurol Genet. 2019 Oct 23;5(6):e367
pubmed: 31872051
Lancet. 2012 Nov 10;380(9854):1674-82
pubmed: 23020937
BMC Med Genet. 2017 Oct 25;18(1):119
pubmed: 29070031
Hum Genet. 2017 Jul;136(7):821-834
pubmed: 28393272
Am J Med Genet A. 2015 Sep;167A(9):2017-25
pubmed: 25914188